Chimerix

2009

Chimerix to Present at Two Upcoming Investor Conferences    

RESEARCH TRIANGLE PARK, NC, November 12, 2009 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a… > Read More

Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox    

RESEARCH TRIANGLE PARK, NC, November 6, 2009 - Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001,… > Read More

Chimerix Raises $16.1 Million in Series E Financing    

RESEARCH TRIANGLE PARK, NC, August 11, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, today announced the completion of a $16.1 million Series E financing.  Leading life science venture capital investors Canaan… > Read More

Chimerix, Inc., Appoints Kenneth I. Moch Chief Operating Officer    

RESEARCH TRIANGLE PARK, NC, July 16, 2009 – Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Kenneth I. Moch has joined the company as Chief Operating Officer.

Mr. Moch brings more than 25 years of experience… > Read More

Chimerix Joins International Network of Organizations to Cure Malaria    

RESEARCH TRIANGLE PARK, NC, April 2, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has joined the Medicines for Malaria Venture (MMV) and its network of public-private partnerships… > Read More